The technological innovation in the biomedicine field in ChinaZHANG Ting, LU Yan, CHEN Juan, OUYANG Zhao-lian2521-2527
A preliminary study on the construction of U.S.FDA centers of excellence in regulatory science and innovationZHANG Ya-juan, YANG Jing-shu, SUN Wen-shuang, YANG Yue2528-2534
Research on the risk-based drug inspection program of FDA and the referential significance to ChinaYANG Lu-yao, YANG Yue2535-2540
The main topics and development context of drug repositioning research in ChinaTAI Yang-fang, WANG Shuai, ZHANG Fen-li, YU Qi, HE Pei-feng2541-2551
Semaglutide:first oral glucagon-like peptide-1 receptor agonistZHANG Wen-zhu, SUN Tao-hua, SHI Jie2552-2556
The first drug for the treatment of neurofibromatosis type 1 in pediatric patients:selumetinibNI Wen-qi, LIU Xiao-ying, ZHU Feng2557-2560
Common statistical design questions consulted in communication meetings on protocols of registered clinical trialsPAN Jian-hong, ZHAO Jun, LI Ruo-bing, HAN Jing-jing, ZHANG Hui, WANG Jun2565-2569
Status of validation and qualification of biomarkers and considerations on the scientific regulationZHU Si-rui, ZHOU Xiao-bing, HUANG Zhi-ying, ZHANG He-zhan, Li Bo2570-2575
Advances in bone mesenchymal stem cells treatment to promote neurorestorative effects after ischemic strokeYANG Ran, SHEN Yan-jia, CHEN Miao, ZHANG Wen, KONG Ling-lei, LI Li, DU Guan-hua2576-2579